Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366177283> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4366177283 endingPage "S74" @default.
- W4366177283 startingPage "S74" @default.
- W4366177283 abstract "While several medications are known to induce dermatomyositis (DM), most existing studies are case reports or small case series from a single institution. There is also limited information on DM induced by immune checkpoint inhibitors (ICIs), which are increasingly used in oncologic therapy. To characterize the clinical presentation, risk factors, management, and outcomes of drug-induced DM based on the current literature, a systematic review was performed in PubMed on August 22, 2022, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. Articles meeting preestablished inclusion criteria (written in English; original articles, case reports, literature reviews, and observation letters) were selected, and data abstracted. Articles that met the scope of the review were also added from reference lists. When possible, study results were quantitatively combined. In 135 studies (114 from the literature search and 21 additional studies pulled from reference lists) describing 179 cases, 58% of patients were female and the median age was 59 years (range 10-85 years). The most common associated medications were hydroxyurea (25%), statins (23%), ICIs (15%), chemotherapeutic agents (6.7%), penicillamine (5.6%), and tumor necrosis factor inhibitors (5.6%). Histopathologic testing, when undertaken, was helpful in establishing the diagnosis. The latency between initiation of drug and DM onset ranged from a few days to 10 years. History of malignancy was reported in 45% of cases. Treatments included discontinuation of the culprit medication, topical and systemic corticosteroids, steroid-sparing agents (methotrexate, mycophenolate, azathioprine, dapsone), intravenous immunoglobulin, and antimalarials. Most cases with reported outcomes improved to some degree with these interventions. Drug-induced DM can be associated with multiple types of medications including chemo- and immunotherapies. It is essential that dermatologists recognize drug-induced DM so that they can guide prompt management and minimize interruption of therapy when possible." @default.
- W4366177283 created "2023-04-19" @default.
- W4366177283 creator A5005581259 @default.
- W4366177283 creator A5079965894 @default.
- W4366177283 creator A5082668988 @default.
- W4366177283 date "2023-05-01" @default.
- W4366177283 modified "2023-09-28" @default.
- W4366177283 title "427 Drug-induced dermatomyositis: A systematic review" @default.
- W4366177283 doi "https://doi.org/10.1016/j.jid.2023.03.433" @default.
- W4366177283 hasPublicationYear "2023" @default.
- W4366177283 type Work @default.
- W4366177283 citedByCount "0" @default.
- W4366177283 crossrefType "journal-article" @default.
- W4366177283 hasAuthorship W4366177283A5005581259 @default.
- W4366177283 hasAuthorship W4366177283A5079965894 @default.
- W4366177283 hasAuthorship W4366177283A5082668988 @default.
- W4366177283 hasBestOaLocation W43661772831 @default.
- W4366177283 hasConcept C126322002 @default.
- W4366177283 hasConcept C141071460 @default.
- W4366177283 hasConcept C16005928 @default.
- W4366177283 hasConcept C17744445 @default.
- W4366177283 hasConcept C177713679 @default.
- W4366177283 hasConcept C189708586 @default.
- W4366177283 hasConcept C199539241 @default.
- W4366177283 hasConcept C2776760755 @default.
- W4366177283 hasConcept C2777640609 @default.
- W4366177283 hasConcept C2778715236 @default.
- W4366177283 hasConcept C2778751314 @default.
- W4366177283 hasConcept C2779134260 @default.
- W4366177283 hasConcept C2779399171 @default.
- W4366177283 hasConcept C2779473830 @default.
- W4366177283 hasConcept C2780035454 @default.
- W4366177283 hasConcept C71924100 @default.
- W4366177283 hasConcept C98274493 @default.
- W4366177283 hasConceptScore W4366177283C126322002 @default.
- W4366177283 hasConceptScore W4366177283C141071460 @default.
- W4366177283 hasConceptScore W4366177283C16005928 @default.
- W4366177283 hasConceptScore W4366177283C17744445 @default.
- W4366177283 hasConceptScore W4366177283C177713679 @default.
- W4366177283 hasConceptScore W4366177283C189708586 @default.
- W4366177283 hasConceptScore W4366177283C199539241 @default.
- W4366177283 hasConceptScore W4366177283C2776760755 @default.
- W4366177283 hasConceptScore W4366177283C2777640609 @default.
- W4366177283 hasConceptScore W4366177283C2778715236 @default.
- W4366177283 hasConceptScore W4366177283C2778751314 @default.
- W4366177283 hasConceptScore W4366177283C2779134260 @default.
- W4366177283 hasConceptScore W4366177283C2779399171 @default.
- W4366177283 hasConceptScore W4366177283C2779473830 @default.
- W4366177283 hasConceptScore W4366177283C2780035454 @default.
- W4366177283 hasConceptScore W4366177283C71924100 @default.
- W4366177283 hasConceptScore W4366177283C98274493 @default.
- W4366177283 hasIssue "5" @default.
- W4366177283 hasLocation W43661772831 @default.
- W4366177283 hasOpenAccess W4366177283 @default.
- W4366177283 hasPrimaryLocation W43661772831 @default.
- W4366177283 hasRelatedWork W2078168033 @default.
- W4366177283 hasRelatedWork W2313871464 @default.
- W4366177283 hasRelatedWork W2398224903 @default.
- W4366177283 hasRelatedWork W2416755235 @default.
- W4366177283 hasRelatedWork W2617552567 @default.
- W4366177283 hasRelatedWork W2955383188 @default.
- W4366177283 hasRelatedWork W3012593498 @default.
- W4366177283 hasRelatedWork W3047967522 @default.
- W4366177283 hasRelatedWork W4242153503 @default.
- W4366177283 hasRelatedWork W4298082289 @default.
- W4366177283 hasVolume "143" @default.
- W4366177283 isParatext "false" @default.
- W4366177283 isRetracted "false" @default.
- W4366177283 workType "article" @default.